首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   44458篇
  免费   2517篇
  国内免费   156篇
耳鼻咽喉   562篇
儿科学   1442篇
妇产科学   1225篇
基础医学   7290篇
口腔科学   964篇
临床医学   3601篇
内科学   8493篇
皮肤病学   1235篇
神经病学   4574篇
特种医学   2320篇
外国民族医学   14篇
外科学   6089篇
综合类   200篇
一般理论   9篇
预防医学   2218篇
眼科学   807篇
药学   3075篇
中国医学   42篇
肿瘤学   2971篇
  2022年   339篇
  2021年   563篇
  2020年   431篇
  2019年   557篇
  2018年   666篇
  2017年   598篇
  2016年   811篇
  2015年   878篇
  2014年   1132篇
  2013年   1474篇
  2012年   2167篇
  2011年   2372篇
  2010年   1308篇
  2009年   1379篇
  2008年   2282篇
  2007年   2452篇
  2006年   2317篇
  2005年   2311篇
  2004年   2136篇
  2003年   2155篇
  2002年   2045篇
  2001年   1169篇
  2000年   1118篇
  1999年   1041篇
  1998年   658篇
  1997年   521篇
  1996年   443篇
  1995年   395篇
  1994年   353篇
  1993年   353篇
  1992年   617篇
  1991年   631篇
  1990年   610篇
  1989年   515篇
  1988年   509篇
  1987年   506篇
  1986年   478篇
  1985年   471篇
  1984年   372篇
  1983年   297篇
  1982年   232篇
  1981年   244篇
  1980年   230篇
  1979年   319篇
  1978年   248篇
  1977年   236篇
  1976年   216篇
  1975年   227篇
  1974年   264篇
  1973年   219篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation.  相似文献   
2.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Akteure der öffentlichen Gesundheit (Public Health) tragen wesentlich zu Gesundheitsschutz, -förderung und...  相似文献   
3.
4.
5.
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies.  相似文献   
6.
7.
8.
Hawi  N.  von Falck  C.  Krettek  C.  Meller  R. 《Der Unfallchirurg》2019,122(12):944-949
Die Unfallchirurgie - Zur Diagnostik von Schultergelenkerkrankungen wird routinemäßig die Magnetresonanztomographie (MRT) durchgeführt. Diese kann entsprechend der klinischen...  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号